Roche Media Release: Roche launches new ProGRP test for more precise diagnosis in lung cancer Donnerstag, 18. Juli 2013 - 07:03

Roche launches new ProGRP test for more precise diagnosis in lung cancer New test expands cancer diagnostics portfolio and strengthens Roche Diagnostics’ comprehensive tumour marker menu

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the global launch (except US) of Elecsys ProGRP, a test that distinguishes between the two main types of lung cancer – small cell (SCLC) and non-small cell (NSCLC) lung cancer – and can help diagnose early-stage SCLC. Correct differential diagnosis in lung cancer is important, as the two types have different prognoses and must be treated differently: early-stage NSCLC can be cured by surgery, while SCLC is treated with chemo- and radiotherapy. Studies have shown that ProGRP as a standalone test is superior to the current standard neuron-specific enolase (NSE)  test and that measuring both ProGRP and NSE enhances diagnostic accuracy.

The ProGRP test from Roche is the first which can be determined in serum or plasma. This allows a combined application with NSE from a single sample tube. Healthcare professionals benefit from ProGRP by improved determination of the histological subtype if biopsy results are unclear.

“As a leader in oncology, Roche is committed to providing reliable diagnostic tests to enable earlier detection of cancer,” said Roland Diggelmann, COO Division Roche Diagnostics. “Until now, patients with SCLC have usually been diagnosed only when the disease has reached an advanced stage, when the chances of a cure are very low. ProGRP meets a medical need for more precise diagnosis, supporting medical decision making and helping healthcare professionals to improve patient outcomes.” more

With best regards, Roche Group Media Relations

Roche Group Media Relations Grenzacherstrasse 124 4070 Basel, Switzerland

Phone: +41 61 688 88 88 Fax: +41 61 688 27 75 mailto:roche.mediarelations@roche.com www.roche.com